Keep Current with the Latest in Cell Biology Research
Block title
The Pancreatic Cancer Secretome Activates the STAT3 Signaling in Pancreatic Stellate Cells to Drive the Secretion of Muscle Atrophy-Inducing Factors
[Scientific Reports] Scientists treated pancreatic stellate cells with conditioned medium from various pancreatic cancer cells (CCM). They revealed that CCM consistently activates STAT3 to secrete muscle atrophy-inducing factors from stellate cells and that the secretion was not observed when CCM from brefeldin A-treated cancer cells was added.
Isofalcarintriol Ameliorates Gestational Diabetes Mellitus-Induced β-Cell Dysfunction by Targeting MIF to Enhance Mitophagy
[Communications Biology] The authors investigated the role of isofalcarintriol (IFT), a carrot-derived polyacetylene, in regulating mitochondrial function in gestational diabetes mellitus-related β-cells.
OU Researcher Studies How Dietary Fat May Affect Pancreatic Tumors
[University of Oklahoma] With a five-year, $2.6 million grant from the National Cancer Institute, Dr. Kamiya Mehla will investigate how a diet high in saturated fats may contribute to tumor growth by weakening the body’s anti-tumor immune response and changing how cancer cells use fats.
Rezolute Announces Positive Results from the Phase III upLIFT Study in Tumor Hyperinsulinism
[Rezolute, Inc.] Rezolute, Inc. announced positive results from the ongoing open-label Phase III upLIFT study of ersodetug in tumor hyperinsulinism, in which the primary efficacy endpoint has been achieved, based on preliminary results.
ECHS1 K115 Succinylation Inhibits Fatty Acid β-Oxidation in Pancreatic Ductal Adenocarcinoma
[Cell Reports] Toward understanding the lysine succinylation that regulates PDAC development, scientists conduct a comprehensive succinylproteome study on a prospectively collected PDAC cohort.
Depletion of Endogenous IL-18 Suppresses Pancreatic Cancer Progression, Reprograms the Tumor Microenvironment, and Enhances KRAS Inhibitor Efficacy
[Gastroenterology] Investigators generated genetically engineered mouse models with IL-18 depletion in the context of spontaneous PDAC development. They used single-cell RNA-sequencing and functional assays to analyze PDAC progression, macrophage phenotypes, and cancer cell-macrophage interactions.
Targeting ELF3 with Biomimetic Nanotherapy Sensitizes PDAC to Gemcitabine via GSDME-Mediated Pyroptosis
[Pharmacological Research] Researchers developed a biomimetic nanoplatform using cancer cell membrane-coated ZIF-8 nanoparticles to co-deliver gemcitabine and an E74-like factor 3 (ELF3)-targeting shRNA.
Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
[Cancer Research] The authors showed that the Tn antigen, a truncated O-glycan, reshapes the tumor immune landscape of PDAC. Expression of Tn antigen on PDAC cells enhances proliferation in vitro and tumor growth in vivo.
Inkjet-Printed Single Cell-Derived Pancreatic Cancer Organoid for Intratumoral Heterogeneity Quantification
[Biofabrication] Investigators presented a high-resolution, drop-on-demand inkjet bioprinting platform for generating single cell-derived PDAC organoids to systematically investigate clonal heterogeneity.
Monitoring the Metabolic Microenvironment of Insulin-Secreting and Insulin-Responsive Cells: Sensing Technologies, Byproduct Dynamics, and Culture-Health Prediction
[Molecular Metabolism] The authors map the real-time sensing of the metabolic microenvironment for insulin-secreting and insulin-responsive cell models, with the aim of distinguishing genuine metabolic dysfunction from artefacts of the culture system.
Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
[Adagene Inc. ] Adagene Inc. and City of Hope announced the launch of an innovative Phase I clinical trial to explore a new combination therapy for patients battling metastatic colorectal cancer. The trial will evaluate ivonescimab, which activates the immune system's T cells to attack cancer cells, and muzastotug, which enhances the immune system’s ability to recognize and destroy cancer.
Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy
[Genentech] Genentech announced that the US FDA has approved Gazyva® (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy, a chronic autoimmune disease that can lead to kidney failure, at risk of disease progression.

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
